L Jeffrey Medeiros Selected Research

Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)

1/2022	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma.
12/2021	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship.
12/2021	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease.
1/2021	MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma.
6/2020	B-cell lymphomas associated with breast implants: Report of three cases and review of the literature.
4/2020	Reconsideration of the first recognition of breast implant-associated anaplastic large cell lymphoma: A critical review of the literature.
1/2020	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
1/2020	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.
1/2020	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
1/2020	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

L Jeffrey Medeiros Research Topics

Disease

190	Neoplasms (Cancer) 05/2022 - 02/2002
91	Lymphoma (Lymphomas) 02/2022 - 02/2002
63	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022 - 05/2002
54	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 06/2002
48	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 02/2004
39	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 02/2002
37	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2022 - 05/2002
32	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 11/2002
28	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 05/2002
26	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 10/2007
26	Disease Progression 01/2022 - 01/2007
22	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 09/2002
16	Leukemia 01/2022 - 02/2004
16	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2017 - 04/2002
15	Chromosome Aberrations (Chromosome Abnormalities) 11/2021 - 01/2007
15	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 05/2002
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 11/2002
13	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022 - 11/2002
10	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 12/2010
10	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 05/2002
9	Residual Neoplasm 01/2021 - 02/2002
9	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2020 - 11/2002
8	Multiple Myeloma 06/2019 - 09/2004
8	Waldenstrom Macroglobulinemia (Macroglobulinemia) 10/2017 - 11/2002
8	Genetic Translocation (Chromosomal Translocation) 10/2015 - 04/2002
7	Eosinophilia 01/2022 - 05/2003
7	Philadelphia Chromosome 01/2019 - 11/2010
7	Acute Promyelocytic Leukemia 01/2015 - 03/2004
6	Primary Myelofibrosis (Myelosclerosis) 02/2022 - 07/2004
6	Carcinoma (Carcinomatosis) 01/2019 - 06/2005
6	Carcinogenesis 07/2013 - 03/2006
5	Blast Crisis (Blast Phase) 01/2021 - 03/2011
5	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2019 - 10/2009
5	Fibrosis (Cirrhosis) 01/2018 - 07/2004
5	Mycosis Fungoides 04/2015 - 09/2002
4	Lymphadenopathy 02/2021 - 02/2002
4	Cytopenia 01/2020 - 03/2010
4	Epstein-Barr Virus Infections 04/2019 - 08/2013
4	Burkitt Lymphoma (Burkitt's Lymphoma) 10/2017 - 11/2002

Drug/Important Bio-Agent (IBA)

46	Proteins (Proteins, Gene)FDA Link 02/2022 - 02/2002
41	Rituximab (Mabthera)FDA Link 10/2022 - 02/2002
37	Anaplastic Lymphoma KinaseIBA 01/2021 - 09/2002
23	Biological ProductsIBA 05/2022 - 08/2005
23	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2021 - 03/2002
22	Cyclin D1IBA 01/2022 - 05/2002
19	Biomarkers (Surrogate Marker)IBA 02/2022 - 12/2007
19	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 06/2008
17	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 08/2002
17	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 03/2002
14	AntigensIBA 01/2022 - 02/2002
14	ParaffinIBA 11/2021 - 02/2002
14	Tyrosine Kinase InhibitorsIBA 01/2020 - 09/2011
13	Prednisone (Sone)FDA LinkGeneric 01/2020 - 03/2002
12	Messenger RNA (mRNA)IBA 02/2022 - 05/2002
12	Phosphotransferases (Kinase)IBA 01/2021 - 08/2004
12	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 04/2013 - 04/2002
11	RNA (Ribonucleic Acid)IBA 11/2021 - 04/2004
11	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 10/2005
11	Formaldehyde (Formol)FDA Link 01/2017 - 09/2003
10	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 10/2005
10	AntibodiesIBA 10/2018 - 04/2004
10	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018 - 02/2002
9	Immunoglobulin M (IgM)IBA 08/2019 - 08/2003
8	Capsules (Microcapsules)IBA 12/2021 - 07/2012
8	CytokinesIBA 01/2021 - 11/2004
8	Immunoglobulins (Immunoglobulin)IBA 10/2020 - 01/2011
8	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 07/2004
8	ParaproteinsIBA 08/2019 - 03/2002
7	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 02/2002
7	Peroxidase (Myeloperoxidase)IBA 01/2019 - 08/2005
7	Pyridinolcarbamate (P23)IBA 11/2014 - 05/2002
6	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2021 - 09/2015
6	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021 - 03/2007
6	NF-kappa B (NF-kB)IBA 12/2016 - 02/2004
6	NucleophosminIBA 01/2016 - 07/2006
6	MicroRNAs (MicroRNA)IBA 06/2015 - 07/2011
6	fludarabineIBA 06/2012 - 02/2002
5	ibrutinibIBA 10/2022 - 01/2016
5	LigandsIBA 01/2020 - 01/2006
5	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 05/2015
5	Granzymes (Granzyme)IBA 04/2019 - 11/2012
5	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2018 - 01/2011
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2018 - 02/2009
5	NucleotidesIBA 01/2017 - 02/2012
5	TOR Serine-Threonine KinasesIBA 12/2010 - 07/2006
4	Immunoglobulin G (IgG)IBA 10/2020 - 05/2016
4	Reticulin (Reticular Fiber)IBA 01/2018 - 07/2004
4	Transcription Factors (Transcription Factor)IBA 10/2017 - 06/2005
4	PAX5 Transcription FactorIBA 10/2017 - 04/2004
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2017 - 01/2006

Therapy/Procedure

153	Therapeutics 01/2022 - 05/2002
49	Drug Therapy (Chemotherapy) 01/2021 - 02/2002
21	Breast Implants (Breast Implant) 12/2021 - 09/2009
19	Radiotherapy 01/2021 - 03/2002
15	Stem Cell Transplantation 01/2022 - 10/2006
6	Splenectomy 01/2017 - 04/2006
5	Immunotherapy 01/2020 - 01/2018
5	Aftercare (After-Treatment) 01/2020 - 01/2004
4	Hematopoietic Stem Cell Transplantation 02/2022 - 08/2014
4	Induction Chemotherapy 10/2018 - 05/2003